PEGylation of a factor VIII-phosphatidylinositol complex: Pharmacokinetics and immunogenicity in hemophilia A mice

AAPS Journal

Volumn 14, Issue 1, 2012, Pages 35-42

  Peng, Aaron ^a   Kosloski, Matthew P ^a   Nakamura, Genki ^a   Ding, Hong ^a   Balu Iyer, Sathy V ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

factor VIII; hemophilia A; immunogenicity; inhibitor development; PEGylation

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 DERIVATIVE; MACROGOL; MONOCLONAL ANTIBODY; PEGYLATED FACTOR 8 PHOSPHATIDYLINOSITOL CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; FEMALE; HEMOPHILIA A; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOPHARMACEUTICS; NONHUMAN; SINGLE DRUG DOSE;

ANIMALS; AREA UNDER CURVE; COAGULANTS; FACTOR VIII; FEMALE; HALF-LIFE; HEMOPHILIA A; INFUSIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOLS; POLYETHYLENE GLYCOLS;

EID: 84857627016     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9309-2     Document Type: Article

References (60)

1. PA Foster TS Zimmerman 1989 Factor VIII structure and function Blood Rev. 3 3 180 91 2506958 10.1016/0268-960X(89)90015-5 1:STN:280: DyaK3c%2FgtFOjtA%3D%3D (Pubitemid 19243405)
2. PM Mannucci EG Tuddenham 2001 The hemophilias-from royal genes to gene therapy N. Engl. J. Med. 344 23 1773 9 10.1056/NEJM200106073442307 11396445 10.1056/NEJM200106073442307 1:CAS:528:DC%2BD3MXkslKqsbo%3D (Pubitemid 32497033)
3. J Klinge NM Ananyeva CA Hauser EL Saenko 2002 Hemophilia A-from basic science to clinical practice Semin. Thromb. Hemost. 28 3 309 22 10.1055/s-2002-32667 12098093 10.1055/s-2002-32667 1:CAS:528: DC%2BD38XlsVKksbg%3D (Pubitemid 34634346)
4. DB Brettler 1996 Inhibitors in congenital haemophilia Baillieres Clin Haematol. 9 2 319 29 8800508 10.1016/S0950-3536(96)80066-7 1:STN:280: DyaK28zptlOgtw%3D%3D (Pubitemid 26185951)
5. JF Healey IM Lubin H Nakai EL Saenko LW Hoyer D Scandella, et al. 1995 Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII J. Biol. Chem. 270 24 14505 9 7540171 10.1074/jbc.270.24.14505 1:CAS:528:DyaK2MXmsVSitL4%3D
6. IM Lubin JF Healey RT Barrow D Scandella P Lollar 1997 Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis J. Biol. Chem. 272 48 30191 5 9374501 10.1074/jbc.272.48.30191 1:CAS:528: DyaK2sXnslGhtbk%3D (Pubitemid 27512220)
7. D Zhong EL Saenko M Shima M Felch D Scandella 1998 Some human inhibitor antibodies interfere with factor VIII binding to factor IX Blood 92 1 136 42 9639509 1:CAS:528:DyaK1cXktleru78%3D (Pubitemid 28303185)
8. JF Healey RT Barrow HM Tamim IM Lubin M Shima D Scandella, et al. 1998 Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII Blood 92 10 3701 9 9808564 1:CAS:528:DyaK1cXnsVKltr8%3D (Pubitemid 28525197)
9. D Scandella GE Gilbert M Shima H Nakai C Eagleson M Felch, et al. 1995 Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site Blood 86 5 1811 9 7544643 1:CAS:528:DyaK2MXnslKrur8%3D
10. PJ Fay D Scandella 1999 Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa J. Biol. Chem. 274 42 29826 30 10514461 10.1074/jbc.274.42.29826 1:CAS:528:DyaK1MXmvVajsLg%3D (Pubitemid 29483358)
11. K Fijnvandraat PH Celie EA Turenhout JW ten Cate JA van Mourik K Mertens, et al. 1998 A human alloantibody interferes with binding of factor IXa to the factor VIII light chain Blood 91 7 2347 52 9516133 1:CAS:528:DyaK1cXitF2hs74%3D (Pubitemid 28155508)
12. MT Reding DK Okita BM Diethelm-Okita TA Anderson BM Conti-Fine 2003 Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII J. Thromb. Haemost. 1 8 1777 84 12911593 10.1046/j.1538-7836.2003.00251.x 1:CAS:528:DC%2BD2cXktFGktbs%3D
13. MT Reding DK Okita BM Diethelm-Okita TA Anderson BM Conti-Fine 2004 Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII J. Thromb. Haemost. 2 8 1385 94 15304045 10.1111/j.1538-7836.2004. 00850.x 1:CAS:528:DC%2BD2cXns1ais7k%3D (Pubitemid 40186136)
14. GL Hu DK Okita BM Conti-Fine 2004 T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects J. Thromb. Haemost. 2 11 1908 17 15550021 10.1111/j.1538-7836.2004.00918.x 1:CAS:528:DC%2BD2cXhtFagsLzI (Pubitemid 40192743)
15. M Morfini 2003 Pharmacokinetics of factor VIII and factor IX Haemophilia. 9 Suppl 1 94 9 12709044 10.1046/j.1365-2516.9.s1.8.x 1:CAS:528: DC%2BD3sXks1agtrc%3D discussion 100
16. D Eaton H Rodriguez GA Vehar 1986 Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity Biochemistry 25 2 505 12 3082357 10.1021/bi00350a035 1:CAS:528: DyaL28Xos1Sjsw%3D%3D (Pubitemid 16053817)
17. PJ Fay MT Anderson SI Chavin VJ Marder 1986 The size of human factor VIII heterodimers and the effects produced by thrombin Biochim. Biophys. Acta 871 3 268 78 3085715 10.1016/0167-4838(86)90208-6 1:CAS:528:DyaL28XktlOkurc%3D (Pubitemid 16056673)
18. PJ Lenting JG Neels BM van den Berg PP Clijsters DW Meijerman H Pannekoek, et al. 1999 The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein J. Biol. Chem. 274 34 23734 9 10446132 10.1074/jbc.274.34.23734 1:CAS:528:DyaK1MXlsVOns7c%3D (Pubitemid 29390294)
19. EL Saenko AV Yakhyaev I Mikhailenko DK Strickland AG Sarafanov 1999 Role of the low density lipoprotein-related protein receptor in mediation of factor VIII catabolism J. Biol. Chem. 274 53 37685 92 10608826 10.1074/jbc.274.53.37685 1:CAS:528:DC%2BD3cXkt1Ghtg%3D%3D (Pubitemid 30026827)
20. R Ljung 2009 Prophylactic therapy in haemophilia Blood Rev. 23 6 267 74 10.1016/j.blre.2009.08.001 19775786 10.1016/j.blre.2009.08.001 1:CAS:528:DC%2BD1MXhsFaitr3E
21. M Carlsson E Berntorp S Bjorkman K Lindvall 1993 Pharmacokinetic dosing in prophylactic treatment of hemophilia A Eur. J. Haematol. 51 4 247 52 8243614 10.1111/j.1600-0609.1993.tb00638.x 1:STN:280:DyaK2c%2FmtlSiuw%3D%3D (Pubitemid 24014154)
22. A Sharathkumar D Lillicrap VS Blanchette M Kern J Leggo AM Stain, et al. 2003 Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A J. Thromb. Haemost. 1 6 1228 36 12871324 10.1046/j.1538-7836.2003.00230.x 1:CAS:528:DC%2BD2cXktFOisr4%3D
23. M Koestenberger W Raith W Muntean 2000 High titre inhibitor after continuous factor VIII administration for surgery in a young infant Haemophilia 6 2 120 10781202 10.1046/j.1365-2516.2000.00377.x 1:STN:280: DC%2BD3c3ksVSnsA%3D%3D (Pubitemid 30166837)
24. AJ Claxton J Cramer C Pierce 2001 A systematic review of the associations between dose regimens and medication compliance Clin. Ther. 23 8 1296 310 11558866 10.1016/S0149-2918(01)80109-0 1:STN:280:DC%2BD3MrhtVKktA%3D%3D (Pubitemid 32804122)
25. K Ramani RD Miclea VS Purohit DE Mager RM Straubinger SV Balu-Iyer 2008 Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A J. Pharm. Sci. 97 4 1386 98 10.1002/jps.21102 17705286 10.1002/jps.21102 1:CAS:528: DC%2BD1cXkt1CgsLk%3D
26. TS Levchenko R Rammohan AN Lukyanov KR Whiteman VP Torchilin 2002 Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating Int. J. Pharm. 240 1-2 95 102 12062505 10.1016/S0378-5173(02)00129-1 1:CAS:528:DC%2BD38Xktlaru7o%3D (Pubitemid 34607706)
27. VD Awasthi D Garcia BA Goins WT Phillips 2003 Circulation and biodistribution profiles of long-circulating PEG-liposomes of various sizes in rabbits Int. J. Pharm. 253 1-2 121 32 12593943 10.1016/S0378-5173(02)00703-2 1:CAS:528:DC%2BD3sXht1Wmsbk%3D (Pubitemid 36204032)
28. TM Allen C Hansen F Martin C Redemann A Yau-Young 1991 Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo Biochim. Biophys. Acta 1066 1 29 36 2065067 10.1016/0005-2736(91)90246-5 1:CAS:528:DyaK3MXkslyrsr8%3D
29. R Zeisig K Shimada S Hirota D Arndt 1996 Effect of sterical stabilization on macrophage uptake in vitro and on thickness of the fixed aqueous layer of liposomes made from alkylphosphocholines Biochim. Biophys. Acta 1285 2 237 45 8972708 10.1016/S0005-2736(96)00167-8 1:CAS:528:DyaK28XmvFalsr0%3D (Pubitemid 26403082)
30. K Ramani V Purohit R Miclea P Gaitonde RM Straubinger SV Balu-Iyer 2008 Passive transfer of polyethylene glycol to liposomal-recombinant human FVIII enhances its efficacy in a murine model for hemophilia A J. Pharm. Sci. 97 9 3753 64 10.1002/jps.21266 18300296 10.1002/jps.21266 1:CAS:528: DC%2BD1cXhtVyltL7O
31. A Peng RM Straubinger SV Balu-Iyer 2010 Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice AAPS J. 12 3 473 81 10.1208/s12248-010-9207-z 20517659 10.1208/s12248-010-9207-z 1:CAS:528:DC%2BC3cXovVKnsL0%3D
32. S Stoilova-McPhie BO Villoutreix K Mertens G Kemball-Cook A Holzenburg 2002 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography Blood 99 4 1215 23 11830468 10.1182/blood.V99.4.1215 1:CAS:528:DC%2BD38XhtlWqsLY%3D (Pubitemid 34547073)
33. KP Pratt BW Shen K Takeshima EW Davie K Fujikawa BL Stoddard 1999 Structure of the C2 domain of human factor VIII at 1.5 A resolution Nature 402 6760 439 42 10586887 10.1038/46601 1:CAS:528:DyaK1MXnvFSisrs%3D (Pubitemid 129544835)
34. VS Purohit K Ramani RS Kashi MJ Durrani TJ Kreiger SV Balasubramanian 2003 Topology of factor VIII bound to phosphatidylserine-containing model membranes Biochim. Biophys. Acta 1617 1-2 31 8 14637017 1:CAS:528: DC%2BD3sXptVShsb0%3D (Pubitemid 37456710)
35. GR Bartlett 1959 Phosphorus assay in column chromatography J. Biol. Chem. 234 3 466 8 13641241 1:CAS:528:DyaG1MXmtlWjtg%3D%3D
36. TD Heath BA Macher D Papahadjopoulos 1981 Covalent attachment of immunoglobulins to liposomes via glycosphingolipids Biochim. Biophys. Acta 640 1 66 81 6163457 10.1016/0005-2736(81)90532-0 1:CAS:528:DyaL3MXotFyksw%3D%3D (Pubitemid 11133973)
37. L Bi AM Lawler SE Antonarakis KA High JD Gearhart HH Kazazian Jr 1995 Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A Nat. Genet. 10 1 119 21 10.1038/ng0595-119 7647782 10.1038/ng0595-119 1:CAS:528:DyaK2MXlsVymt7o%3D
38. B Verbruggen I Novakova H Wessels J Boezeman M van den Berg E Mauser-Bunschoten 1995 The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability Thromb. Haemost. 73 2 247 51 7792738 1:CAS:528:DyaK2MXjsl2hs70%3D
39. VS Purohit K Ramani R Sarkar HH Kazazian Jr SV Balasubramanian 2005 Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex J. Biol. Chem. 280 18 17593 600 15728582 10.1074/jbc.M500163200 1:CAS:528:DC%2BD2MXjsl2itLk%3D (Pubitemid 41388993)
40. JR Nedelman E Gibiansky DT Lau 1995 Applying Bailer's method for AUC confidence intervals to sparse sampling Pharm. Res. 12 1 124 8 7724473 10.1023/A:1016255124336 1:CAS:528:DyaK2MXjt12it7k%3D
41. EW Davie K Fujikawa W Kisiel 1991 The coagulation cascade: initiation, maintenance, and regulation Biochemistry 30 43 10363 70 1931959 10.1021/bi00107a001 1:CAS:528:DyaK38XhtVejur8%3D
42. P Lollar PJ Fay DN Fass 1993 Factor VIII and factor VIIIa Methods Enzymol. 222 128 43 8412790 10.1016/0076-6879(93)22010-D 1:CAS:528: DyaK2cXht1yhsrY%3D
43. BM Reipert RU Ahmad PL Turecek HP Schwarz 2000 Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A Thromb. Haemost. 84 5 826 32 11127864 1:CAS:528:DC%2BD3cXovFCjsLg%3D
44. A Peng P Gaitonde MP Kosloski RD Miclea P Varma SV Balu-Iyer 2009 Effect of route of administration of human recombinant factor VIII on its immunogenicity in hemophilia A mice J. Pharm. Sci. 98 12 4480 4 10.1002/jps.21765 19499565 10.1002/jps.21765 1:CAS:528:DC%2BD1MXhtlCjsL7F
45. DS Pisal SV Balu-Iyer 2010 Phospholipid binding improves plasma survival of factor VIII Thromb. Haemost. 104 5 1073 5 10.1160/TH10-06-0422 20838749 10.1160/TH10-06-0422 1:CAS:528:DC%2BC3cXhsFaht73E
46. DS Pisal MP Kosloski SV Balu-Iyer 2010 Delivery of therapeutic proteins J. Pharm. Sci. 99 6 2557 75 10.1002/jps.22054 20049941 10.1002/jps.22054 1:CAS:528:DC%2BC3cXkvVOkurY%3D
47. A Abuchowski T van Es NC Palczuk FF Davis 1977 Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 252 11 3578 81 405385 1:CAS:528: DyaE2sXksV2it7c%3D (Pubitemid 8116087)
48. A Abuchowski JR McCoy NC Palczuk T van Es FF Davis 1977 Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252 11 3582 6 16907 1:CAS:528:DyaE2sXksV2ntL4%3D (Pubitemid 8116088)
49. B Mei C Pan H Jiang H Tjandra J Strauss Y Chen, et al. 2010 Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment Blood 116 2 270 9 10.1182/blood-2009-11-254755 20194895 10.1182/blood-2009-11-254755 1:CAS:528:DC%2BC3cXpslSmtr0%3D
50. M Baru L Carmel-Goren Y Barenholz I Dayan S Ostropolets I Slepoy, et al. 2005 Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy Thromb. Haemost. 93 6 1061 8 10.1267/THRO05061061 15968389 1:CAS:528: DC%2BD2MXls1WjtbY%3D (Pubitemid 40823509)
51. NM Ananyeva DV Kouiavskaia M Shima EL Saenko 2001 Catabolism of the coagulation factor VIII: can we prolong lifetime of f VIII in circulation? Trends Cardiovasc Med. 11 6 251 7 11673057 10.1016/S1050-1738(01)00124-4 1:CAS:528:DC%2BD3MXnslCjtL8%3D (Pubitemid 32982917)
52. S Bieri JT Djordjevic NL Daly R Smith PA Kroon 1995 Disulfide bridges of a cysteine-rich repeat of the LDL receptor ligand-binding domain Biochemistry 34 40 13059 65 7548065 10.1021/bi00040a017 1:CAS:528:DyaK2MXotVyrtL4%3D
53. N Bovenschen RC Boertjes G van Stempvoort J Voorberg PJ Lenting AB Meijer, et al. 2003 Low density lipoprotein receptor-related protein and factor IXa share structural requirements for binding to the A3 domain of coagulation factor VIII J. Biol. Chem. 278 11 9370 7 12522143 10.1074/jbc.M212053200 1:CAS:528:DC%2BD3sXhvV2jurw%3D (Pubitemid 36800424)
54. AG Sarafanov NM Ananyeva M Shima EL Saenko 2001 Cell surface heparan sulfate proteoglycans participate in factor VIII catabolism mediated by low density lipoprotein receptor-related protein J. Biol. Chem. 276 15 11970 9 10.1074/jbc.M008046200 11278379 10.1074/jbc.M008046200 1:CAS:528: DC%2BD3MXjtFyltr8%3D
55. N Bovenschen DC Rijken LM Havekes BJ van Vlijmen K Mertens 2005 The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor J. Thromb. Haemost. 3 6 1257 65 10.1111/j.1538-7836.2005.01389.x 15946216 10.1111/j.1538-7836.2005.01389.x 1:CAS:528:DC%2BD2MXms1aqsro%3D (Pubitemid 41725251)
56. AL Klibanov K Maruyama VP Torchilin L Huang 1990 Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1 235 7 2384160 10.1016/0014-5793(90)81016-H 1:CAS:528: DyaK3cXmtFOqtbc%3D (Pubitemid 20233874)
57. Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. Downregulation of CD40 signal and induction of TGF-beta by phosphatidylinositol mediates reduction in immunogenicity against recombinant human factor VIII. J Pharm Sci. 2011; doi: 10.1002/jps.22746.
58. T Ishida K Atobe X Wang H Kiwada 2006 Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection J Control Release. 115 3 251 8 10.1016/j.jconrel.2006.08.017 17045355 10.1016/j.jconrel.2006.08.017 1:CAS:528:DC%2BD28XhtFeitr3L (Pubitemid 44634849)
59. T Ishida M Ichihara X Wang H Kiwada 2006 Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes J Control Release. 115 3 243 50 10.1016/j.jconrel.2006.08.001 17011060 10.1016/j.jconrel.2006.08.001 1:CAS:528:DC%2BD28XhtFeitr3K (Pubitemid 44634842)
60. H Koide T Asai K Hatanaka S Akai T Ishii E Kenjo, et al. 2010 T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes Int. J. Pharm. 392 1-2 218 23 10.1016/j.ijpharm.2010.03.022 20227473 10.1016/j.ijpharm.2010.03.022 1:CAS:528:DC%2BC3cXmtVGrs7s%3D